Eli Lilly (NYSE: LLY) reported earnings on July 24. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Eli Lilly beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased. Non-GAAP earnings per share increased significantly. GAAP earnings per share increased significantly.

Margins grew across the board.

Revenue details
 Eli Lilly reported revenue of $5.93 billion. The 12 analysts polled by S&P Capital IQ predicted a top line of $5.84 billion on the same basis. GAAP reported sales were 5.9% higher than the prior-year quarter's $5.60 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.16. The 15 earnings estimates compiled by S&P Capital IQ predicted $1.01 per share. Non-GAAP EPS of $1.16 for Q2 were 40% higher than the prior-year quarter's $0.83 per share. GAAP EPS of $1.11 for Q2 were 34% higher than the prior-year quarter's $0.83 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 80.3%, 80 basis points better than the prior-year quarter. Operating margin was 26.4%, 490 basis points better than the prior-year quarter. Net margin was 20.3%, 380 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $5.69 billion. On the bottom line, the average EPS estimate is $0.97.

Next year's average estimate for revenue is $22.81 billion. The average EPS estimate is $3.91.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,231 members out of 1,330 rating the stock outperform, and 99 members rating it underperform. Among 395 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 373 give Eli Lilly a green thumbs-up, and 22 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eli Lilly is outperform, with an average price target of $56.29.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Eli Lilly. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.